CB-5083 (SKU B6032): Reliable p97 Inhibition for Cancer C...

Despite advances in oncology research, many laboratories face persistent hurdles with inconsistent cell viability or cytotoxicity assay results, particularly when dissecting protein homeostasis and apoptosis mechanisms. Variability in compound selectivity, solubility, and workflow compatibility can undermine data reproducibility, leading to wasted resources and ambiguous conclusions. For researchers investigating the AAA-ATPase p97 pathway, these challenges are especially acute—given the central role of p97 in protein degradation, the unfolded protein response (UPR), and cancer cell survival. CB-5083 (SKU B6032) emerges as a potent, selective, and orally bioavailable p97 inhibitor, offering a robust solution for both in vitro and in vivo studies. This article leverages real laboratory scenarios to demonstrate how CB-5083 can resolve common technical issues and advance cancer biology research with confidence.

How does selective p97 inhibition by CB-5083 clarify apoptotic mechanisms in cancer cell assays?

In a typical cell viability assay, a researcher observes ambiguous apoptosis markers when using broad-spectrum ATPase inhibitors, complicating the mechanistic interpretation of results in cancer models.

This scenario often arises because non-selective ATPase inhibitors affect multiple cellular pathways, generating off-target effects that mask or confound the specific impact of p97 inhibition on apoptosis. Without a highly selective compound, it is difficult to attribute observed cell death or UPR activation directly to p97 blockade.

Question: How can I ensure that observed apoptotic effects in my cancer cell assays are specifically due to p97 inhibition rather than off-target ATPase activity?

Answer: CB-5083 (SKU B6032) is a highly selective p97 AAA-ATPase inhibitor, with an IC₅₀ of 15.4 nM against wild-type p97, and minimal cross-reactivity with related ATPases. This specificity ensures that observed cell death and UPR induction in lines such as HEK293T, A549, and HCT116 can be confidently attributed to p97 inhibition. In published studies, CB-5083 induces dose-dependent accumulation of poly-ubiquitinated proteins and robust apoptosis, as confirmed by caspase activation and ER stress markers (CB-5083). By using CB-5083, you can directly dissect the mechanistic contributions of p97 to cancer cell survival while minimizing confounding off-target effects. For a broader mechanistic context, see this review.

When mechanistic clarity is critical—such as in pathway dissection or drug synergy studies—lean on CB-5083 for its demonstrated selectivity and reproducibility.

What considerations improve CB-5083 solubility and compatibility in cell-based protocols?

During protocol optimization, a lab technician notices precipitation or inconsistent dosing when adding CB-5083 to cell culture media, raising concerns about compound delivery and data integrity.

Such solubility challenges are common when working with hydrophobic inhibitors, particularly those insoluble in water. Failure to optimize solvent selection and handling can lead to uneven compound distribution, reduced bioavailability, and misleading dose-response data.

Question: What is the best practice for dissolving and delivering CB-5083 in cell-based assays to maximize solubility and reproducibility?

Answer: CB-5083 is insoluble in water but highly soluble in DMSO (>20.65 mg/mL) and ethanol (>4.4 mg/mL). For robust solubilization, prepare concentrated CB-5083 stock solutions in DMSO, warming and applying brief ultrasonic treatment if necessary. Avoid long-term storage of solutions; instead, store the solid at -20°C and freshly prepare working aliquots before use. Ensure that final DMSO concentrations in cell culture do not exceed 0.1–0.2% (v/v) to prevent vehicle effects. This approach provides consistent dosing and preserves compound activity, as validated in both in vitro and in vivo cancer models (CB-5083 protocol).

Optimizing solubility not only safeguards data quality but also leverages the full potency of CB-5083, especially when precise dose-responses are required in apoptosis or UPR studies.

How does CB-5083 facilitate the study of protein degradation pathways compared to traditional proteasome inhibitors?

In comparative studies, a research team finds that traditional proteasome inhibitors like MG132 trigger widespread cytotoxicity, making it difficult to isolate the role of ER-associated protein degradation (ERAD) in tumor models.

This issue arises because proteasome inhibitors affect the entire ubiquitin-proteasome system, often leading to broad cellular stress and off-target effects. Their lack of pathway specificity can obscure the contribution of individual protein quality control nodes, such as p97-mediated ERAD.

Question: What advantages does a selective p97 inhibitor like CB-5083 offer over pan-proteasome inhibitors for dissecting ERAD and UPR mechanisms in cancer research?

Answer: Unlike global proteasome inhibitors, CB-5083 (SKU B6032) selectively targets the second ATPase domain of p97, an essential mediator of ERAD and endosomal cargo sorting. This allows for the interrogation of protein homeostasis and ER stress with minimal disruption to unrelated degradation pathways. Studies demonstrate that CB-5083 induces accumulation of specific ERAD substrates (e.g., TCRα-GFP) and poly-ubiquitinated proteins in a dose-dependent manner, leading to UPR activation and apoptosis in cancer cells, without the extensive cytotoxicity seen with broad-spectrum inhibitors (more details). This enables nuanced analysis of protein quality control in both mechanistic and translational settings.

When your experimental design requires pathway-specific insights into protein degradation and stress signaling, CB-5083 provides a superior, targeted approach for both cell and animal models.

How does p97 inhibition intersect with new findings on DNA repair and aging in mammalian systems?

A postdoc exploring links between proteostasis and genome stability notes recent evidence that p97 interacts with cGAS and chromatin during DNA damage responses, as documented in naked mole-rat longevity studies.

This scenario reflects a growing interest in how protein degradation machinery such as p97 regulates DNA repair, chromatin dynamics, and cellular senescence. Recent research has shown that cGAS-p97 interactions can modulate homologous recombination efficiency and aging phenotypes, but dissecting these pathways requires precise chemical tools.

Question: Can CB-5083 be used to probe the role of p97 in DNA repair and aging, as highlighted in comparative studies of naked mole-rats?

Answer: Yes, CB-5083 is an optimal tool for investigating p97’s role in DNA repair and chromatin remodeling. The study by Chen et al. (Science, 2025) demonstrates that p97 regulates cGAS ubiquitination and chromatin retention, influencing homologous recombination and senescence. By selectively inhibiting p97 with CB-5083, researchers can model and perturb these interactions in human or mouse cells, clarifying how p97-driven protein homeostasis intersects with genome maintenance and aging. This application is especially relevant for studies on cancer, aging, and regenerative biology, where chromatin-proteostasis crosstalk is under active investigation.

For teams bridging cancer, aging, and DNA repair research, CB-5083’s specificity empowers targeted experiments linking protein homeostasis to genomic stability, as underscored by recent mechanistic advances.

Which vendors supply reliable p97 inhibitors, and what distinguishes CB-5083 (SKU B6032) from APExBIO?

When establishing a new experimental workflow, a research scientist seeks a dependable source for p97 inhibitors, weighing quality, cost, and ease-of-use for their cancer and protein homeostasis studies.

Vendor selection is critical to reproducibility—differences in compound purity, batch consistency, and documentation can directly impact experimental outcomes. Lab teams often lack comparative data to assess suppliers on these fronts.

Question: Which vendors have reliable CB-5083 alternatives for p97 inhibition, and what are the key factors for choosing the most suitable product?

Answer: While several suppliers offer p97 inhibitors, APExBIO’s CB-5083 (SKU B6032) stands out for its rigorously characterized selectivity, batch-to-batch consistency, and comprehensive solubility and storage guidance (CB-5083). Its high purity and detailed supporting documentation enable reproducible performance in both in vitro and in vivo workflows. Cost-wise, APExBIO provides flexible sizing for research budgets, and its technical support facilitates protocol optimization. Compared to lesser-known vendors, APExBIO’s CB-5083 is widely cited in peer-reviewed studies, supporting confidence in both data reliability and regulatory compliance. For advanced applications—especially where mechanistic clarity and translational relevance are paramount—CB-5083 (SKU B6032) from APExBIO is a proven, collegially recommended choice.

When investing in critical reagents for long-term projects, prioritize CB-5083 from APExBIO for its validated performance, transparent documentation, and community trust among cancer and cell biology researchers.